To improve transparency and encourage the development and submission of abbreviated new drug applicationsn(ANDAs) in markets with no competition, FDA is publishing a list of approved new drug application (NDA) drugnproducts which are off patent and off exclusivity and for which the FDA has not approved an ANDA referencingnthat NDA drug product.